The reporter of Economic Information Daily learned that the 2022 medical insurance drug catalog access negotiations will be officially launched in early December. At that time, a number of innovative drugs and large varieties of drugs will be included in the medical insurance catalogue, and the coverage of medical insurance will be further expanded. Rongchang Bio's vidicizumab for injection, Kangfang Bio's dual anti drug Cardunizumab, and Mingju Noriki Orensei injection, which is currently purchased at the online price of 1.29 million yuan/needle, will also start the medical insurance negotiation journey one after another. Whether it can enter the medical insurance is worth paying attention. The value purchase benefits more people, said Liu Guoen, director of the China Health Economics Research Center at Peking University. Drug value evaluation is a scientific concept to determine the average price of drugs "on the basis of value". The value purchase of better health output at the same or lower cost really makes "money on the edge". Since 2018, the negotiation on the access of the national medical insurance drug catalog has been carried out for four consecutive years. A total of 250 innovative and life-saving drugs have been added to the catalog through negotiation, with an average price drop of more than 50%. In 2021, 221 negotiation drugs will be reimbursed 140 million person times in total during the agreement period, reducing the burden of patients by 149.49 billion yuan. It is reported that 344 of the 490 declared drugs in 2022 will pass the preliminary examination. Among them, there are 199 drugs out of the catalog, including 144 exclusive western medicines and 14 exclusive Chinese patent medicines. From the perspective of drug category adjustment, the adjustment of medical insurance catalogue adheres to the bottom line principle of "basic insurance". Liu Guoen pointed out that in 2021, for example, 74 new drugs covered 18 kinds of cancer drugs, 20 kinds of drugs for chronic diseases such as hypertension and diabetes, 15 kinds of drugs for anti infection such as hepatitis C and AIDS, and 7 kinds of drugs for rare diseases, which means that the protection for different groups is constantly deepening. He said that the negotiations on the medical insurance catalogue had broken the inherent concept of "innovative drugs=priceless drugs". In 2021, 67 of the 85 drugs out of the list that participated in the negotiations succeeded, with a success rate of 78.8% and a price reduction rate of 61.71%, higher than in 2019 and 2020. Taking anti-tumor drugs as an example, from 2018 to 2021, the proportion of anti-tumor drugs in the national drug negotiations has been maintained at 20% or more, and the average price decline has been maintained at 44% or more. Four innovative domestic drugs have been included in the medical insurance for tumor immunotherapy PD-1, which once had high medical costs. In 2018, the success rate of special anti-cancer drug negotiations reached 94.4%, with an average price drop of 56.7%, which alleviated the drug use problems of cancer patients. The time for innovative drugs to be included in the medical insurance catalogue has been significantly shortened. "Reviewing the calculation process and negotiation results in the past few years, the national medical insurance catalogue gives greater support to" promote innovation "on the basis of" basic insurance "." Liu Guoen said. According to relevant statistics, 27 of the 74 drugs added to the list in 2021 were approved for marketing in that year. In addition, 22 of the 23 major domestic innovative drugs that will enter into negotiations in 2021 have been successfully negotiated. The average cycle of innovative drugs from being approved for marketing to being included in medical insurance is only one year and two months. It is worth mentioning that innovative drugs in China are not only embodied in western medicine